IL33 and psoriasis: In humans, heterogeneous KIT expression is observed under homeostatic conditions in the skin (Figure 3), and cells expressing this protein increase in patients with psoriasis, concomitant with the acquisition of an ILC3 phenotype (129); however, dermal ILC2s maintain their potential since upon stimulation with IL-33 and TSLP they are still capable of producing IL-13 (135).